Directly Evolution to identify potential drugs earlier in discovery.
New Antibody-based drugs to treat disease. Antibodies are produced by the presence of a disease-causing in the laboratory to mimic natural antibodies and are used to treat a number of diseases. Antibody therapies can be highly effective, but challenges can arise. When promising candidate antibodies
this is turn prevents them from being made into a Therapeutic.
New Antibody-based drugs to treat disease. Antibodies are produced by the presence of a disease-causing in the laboratory to mimic natural antibodies and are used to treat a number of diseases. Antibody therapies can be highly effective, but challenges can arise. When promising candidate antibodies are produced at a large scale.
Now research from an 8 years collaboration between a scientist at the University of Leeds and the Bio-pharmaceutical company AstraZeneca has resulted in a technique that allows fragments of antibodies to be screened for susceptibility to aggregation much earlier in the drug discovery process.
The approach is described in the journal (nature communications), published by Dr David Brockwell. Antibody therapeutics have revolutionised medicine. They can be designed to bind to almost any target and are highly specific but research is turning that problem on it is head.
Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of 25hrNews and 25hrNews does not assume any responsibility or liability for the same.
(+91) 8081113111
pr@25hrnews.com
